OpenAlex
PricingAboutJobs
Log inGet started
Author

J. Hou

ORCID: 0009-0004-9541-7569
Observed ORCID: 0009-0004-9541-7569
OpenAlex ID: A5086412230
VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial
2022 · M.R. Mirza, X. Wu, et al. · Annals of Oncology · 10
35O Overall survival of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer adjusted for subsequent PARPi use in placebo group: Results from an ad hoc interim analysis for the phase III NORA study
2023 · X. Wu, J. Zhu, et al. · ESMO Open · 1
PDF
Works count: 2
Citation count: 11
H-index: 1
I10-index: 1
Year
Topic
Type
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security